Teriparatide Plus Zoledronic Acid for Osteogenesis Imperfecta: A Randomized Clinical Trial

Area of Science:

• Orthopedics
• Endocrinology
• Genetics

Background:

• Osteogenesis imperfecta (OI) is a genetic disorder characterized by brittle bones, leading to frequent fractures and significant morbidity.
• Current treatments aim to reduce fracture risk, but optimal therapeutic strategies remain under investigation.

Purpose of the Study:

• To evaluate the efficacy of teriparatide followed by zoledronic acid in reducing fracture risk in adults with OI.
• To assess the impact of this combination therapy on bone mineral density, bone turnover markers, and quality of life.

Main Methods:

• A multicenter, open-label, randomized clinical trial involving adults diagnosed with osteogenesis imperfecta.
• Participants received either teriparatide plus zoledronic acid or standard care, with fracture incidence, bone mineral density (BMD), and quality of life measures assessed.
• The trial included 349 evaluable participants, with fracture risk as the primary endpoint.

Main Results:

• The combination of teriparatide and zoledronic acid did not significantly reduce the incidence of fractures compared to standard care (36.9% vs 36.4%).
• However, this treatment regimen led to significant increases in lumbar spine and total hip BMD.
• Quality of life measures showed some improvements favoring the teriparatide plus zoledronic acid group, with similar adverse event profiles between groups.

Conclusions:

• Teriparatide followed by zoledronic acid did not demonstrate a reduction in fracture risk for adults with osteogenesis imperfecta.
• The findings suggest that bone fragility in OI may be more related to impaired bone quality than solely low bone density.
• Further research is needed to explore therapeutic approaches targeting bone quality in OI.